{
    "2018-02-04": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Benzinga's Weekly Bulls & Bears: AbbVie, Kinder Morgan, Paypay, Starbucks, Wynn And More",
                "features": {
                    "keywords": [
                        "Bulls",
                        "Bears",
                        "AbbVie",
                        "Kinder Morgan",
                        "Paypal",
                        "Starbucks",
                        "Wynn"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "energy",
                        "technology",
                        "consumer goods",
                        "hospitality"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "What to Expect With Gilead Sciences' Q4 Results",
                "features": {
                    "keywords": [
                        "Gilead",
                        "Q4",
                        "Results"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "3 Headwinds in Q4 Earnings Results That Make Merck a Mediocre Stock",
                "features": {
                    "keywords": [
                        "Headwinds",
                        "Q4",
                        "Earnings",
                        "Merck"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "What to Expect With Gilead Sciences' Q4 Results",
                "features": {
                    "keywords": [
                        "Gilead",
                        "Q4",
                        "Results"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}